PSMA-Targeted Therapy Beyond Lu-177 — PatSnap Eureka
PSMA-Targeted Therapy Pipeline Beyond Lutetium-177
Alpha emitters, antibody-drug conjugates, and bispecific T-cell engagers are reshaping the prostate cancer treatment landscape. Explore the next-generation PSMA pipeline—from ²²⁵Ac clinical data to Ambrx ADC patents—powered by PatSnap Eureka.
PSMA: The Dominant Target in Metastatic Prostate Cancer
Prostate-specific membrane antigen (PSMA), also designated folate hydrolase 1 / glutamate carboxypeptidase II, is a type II integral transmembrane glycoprotein overexpressed on prostate cancer epithelial cells at levels up to 1,000-fold above normal tissue. Expression increases proportionally with tumor grade, androgen independence, and metastatic stage—making it an ideal therapeutic target across the disease continuum. Learn more about PSMA's role in the broader context of life sciences drug discovery intelligence.
A critical biological nuance highlighted across multiple retrieved papers is PSMA expression heterogeneity: not all metastases uniformly express PSMA, and a subset of mCRPC patients have PSMA-low or PSMA-negative disease that excludes them from radioligand therapy (RLT). The National Institutes of Health has catalogued extensive research on this heterogeneity challenge.
Research from the University of Duisburg-Essen shows that androgen receptor blockade with enzalutamide upregulates PSMA expression 2.2–2.6-fold in PSMA-low prostate cancer cell lines (22Rv1, C4-2, LNCaP), suggesting pharmacological PSMA upregulation as a strategy to expand the eligible patient population. This AR–PSMA cross-regulation is a central design consideration for next-generation combination regimens.
The Peter MacCallum Cancer Centre explicitly frames resistance mechanisms to [¹⁷⁷Lu]Lu-PSMA as a defining problem for the field—including PSMA downregulation, tumor microenvironment factors, and genomic alterations—providing the biological rationale for the diverse next-generation modalities now entering development. The American Society of Clinical Oncology has highlighted PSMA-targeted therapy as a transformative area in genitourinary oncology.
Seven Approaches Targeting PSMA Beyond the Lu-177 Paradigm
From FDA-approved radioligand therapy to early-stage RNA aptamers, the PSMA-targeted pipeline spans a spectrum of mechanisms designed to overcome resistance, address PSMA-low disease, and reduce normal-tissue toxicity.
¹⁷⁷Lu-PSMA-617 (Pluvicto™)
The FDA-approved standard following the Phase III VISION trial. PSA decline ≥50% reported in 34.5–51% of mCRPC patients across systematic reviews, with hematological toxicity generally CTCAE grade 1–2. A Novartis AG patent (Brazil, 2025, pending) seeks label expansion to taxane-naïve patients post-ARPI.
FDA ApprovedAlpha Emitters: ²²⁵Ac, ²¹²Pb, ²²⁷Th
High LET radiation inducing complex DNA double-strand breaks less amenable to cellular repair than beta radiation. A complete response to [²²⁵Ac]Ac-PSMA-617 is documented in a ¹⁷⁷Lu-refractory mCRPC patient (Istanbul University). A Saarland University cohort (n=15) evaluated tandem ²²⁵Ac/¹⁷⁷Lu regimens in poor-prognosis patients.
Early ClinicalPSMA-Targeted ADCs (Ambrx, Johns Hopkins)
Ambrx, Inc. holds three active patent families across EP and IL jurisdictions covering humanized anti-PSMA ADC scaffolds, all from a 2018 US provisional filing. Johns Hopkins' SBPD-1 couples a PSMA-targeting moiety to MMAE via a cancer-selective cleavable linker, demonstrating high PSMA-binding affinity and favorable in vivo toxicity profile.
Patent / PreclinicalPSMAxCD3 Bispecific T-Cell Engagers
Tübingen's IgG-based PSMAxCD3 bispecific (built on antibody 10B3) induced complete tumor regression in preclinical models—outperforming the Fab-based format due to favorable pharmacokinetics. Aarhus University Hospital identified a high-risk, immunogenic patient subset with high CD8⁺ T-cell infiltration and high PSMA expression as prime candidates via RNA-seq of 126 primary samples.
PreclinicalPSMA-Directed CAR-T Cells
University of Freiburg's D7 scFv CAR-T construct eradicated established prostate cancer xenografts via focal injection; systemic IV delivery combined with low-dose docetaxel induced tumor regression, signaling synergy between CAR-T and cytotoxic chemotherapy in a typically CAR-T-resistant solid tumor context.
PreclinicalRNA Aptamers & Polymersomes
University of Iowa's A9g RNA aptamer targets PSMA's enzymatic activity, inhibiting prostate cancer cell migration and invasion in vitro and reducing metastatic disease in vivo, with confirmed target specificity and absence of immunogenicity. North Dakota State University's reduction-sensitive polymersomes co-encapsulate docetaxel and the HDAC inhibitor mocetinostat for PSMA-targeted delivery.
Early PreclinicalQuantifying the PSMA-Targeted Therapy Landscape
Key data points from patent and literature analysis across alpha emitters, ADC platforms, and clinical efficacy benchmarks.
PSA Response & PSMA Biology: Key Metrics
Clinical and biological benchmarks from systematic reviews and preclinical studies across the PSMA-targeted therapy literature.
Innovation Source Mix: Patent vs. Literature
Academic medical centers dominate the retrieved dataset; commercial patent activity is concentrated in ADC scaffolds (Ambrx) and label expansion (Novartis).
Six Emerging Combination Strategies in the PSMA Pipeline
Retrieved results signal multiple combination strategies designed to overcome resistance, expand eligible patient populations, and optimize pharmacokinetics.
Alpha + Beta Tandem Therapy
The Saarland University cohort (n=15) evaluated [²²⁵Ac]Ac-PSMA-617 augmented [¹⁷⁷Lu]Lu-PSMA-617 in poor-prognosis mCRPC. The rationale: alpha emissions address bulky, high-tumor-burden disease while beta emissions provide crossfire effect to adjacent PSMA-negative cells, particularly in patients with visceral metastases or diffuse bone involvement.
PSMA-RLT + PARP Inhibition
Erasmus MC preclinical data and references to multiple initiated clinical trials indicate PSMA-TRT + PARPi as a leading combination rationale, based on synthetic lethality between ionizing radiation-induced DSBs and impaired base excision repair. Retrieved results note an absence of confirmed preclinical synergism specifically for prostate cancer—flagging a translational gap for drug developers to monitor.
AR Pathway Inhibitors + PSMA-RLT
Enzalutamide-mediated PSMA upregulation (2.2–2.6-fold in vitro, confirmed in PET/CT xenograft models) signals a biologically rational sequencing of AR blockade prior to PSMA-directed therapy, particularly in PSMA-low patients. The PatSnap life sciences platform enables tracking of these combination IP signals across jurisdictions.
CAR-T + Cytotoxic Chemotherapy
University of Freiburg data showing CAR-T + low-dose docetaxel synergy in prostate cancer xenografts signals a potential path for solid tumor CAR-T, where single-agent CAR-T efficacy is typically poor. Systemic IV delivery in combination induced tumor regression—a key proof-of-concept for overcoming the immunosuppressive solid tumor microenvironment.
Who Is Filing PSMA-Targeted Therapy Patents?
Innovation activity in this dataset is distributed across academic medical centers, research institutes, and two commercial entities with concentrated patent portfolios. Track assignee movements with PatSnap Analytics.
| Assignee / Institution | Modality Focus | Evidence Type | Key Signal | Stage |
|---|---|---|---|---|
| Ambrx, Inc. (USA) | Anti-PSMA ADCs | Patent (EP, IL) | 3 active families from 2018 US provisional; humanized antibody scaffolds + cytotoxic payloads | Patent / Preclinical |
| Novartis AG | ¹⁷⁷Lu-PSMA-617 label expansion | Patent (BR, 2025) | Extending approved indication to taxane-naïve mCRPC post-ARPI | Clinical / Pending |
| Johns Hopkins University | ADC prodrugs, PARP imaging, CAR-T tracking | Literature | SBPD-1/MMAE prodrug; [¹⁸F]-PARP-1 PET for alpha therapy monitoring | Preclinical |
| Erasmus University Medical Center | Alpha vs. beta comparison; PSMA + PARPi | Literature | Alpha emitter superiority via DSB complexity; no confirmed PARPi synergism in prostate cancer | Preclinical |
| University of Oslo / Norwegian Radium Hospital | ²¹²Pb-NG001 alpha therapy | Literature | Lead site for ²¹²Pb-NG001; therapeutic index 2.7–3.5; internalization rate as key efficacy predictor | Preclinical |
| Eberhard Karls University Tübingen | PSMAxCD3 bispecific antibodies | Literature | IgG-based format (10B3) achieves complete tumor regression; dual reactivity on tumor cells and neovasculature | Preclinical |
Monitor PSMA Patent Filings Across All Jurisdictions
PatSnap Eureka tracks new filings from Ambrx, Novartis, and emerging academic spinouts in real time.
What the PSMA Pipeline Signals for Drug Developers and IP Teams
Alpha therapy IP is currently under-patented relative to scientific activity. Extensive academic literature on ²²⁵Ac- and ²¹²Pb-PSMA theranostics exists in this dataset without corresponding commercial patent filings, representing a potential freedom-to-operate window—but also a competitive risk if academic developers or radioisotope suppliers move to protect platform chemistry. The European Patent Office database shows limited alpha-emitter PSMA coverage relative to the volume of published preclinical work.
Bispecific T-cell engager strategies face a patient selection challenge. Retrieved results from Aarhus University identify that only a subset of prostate cancer patients—characterized by both high PSMA expression and high CD8⁺ T-cell infiltration across RNA-seq of 126 primary and 17 metastatic samples—are likely candidates, making companion diagnostic development essential before clinical translation of PSMA × CD3 bispecifics.
The PSMA + PARPi clinical translation is advancing ahead of definitive preclinical synergy evidence. Erasmus MC data explicitly note no confirmed synergism in prostate cancer preclinical models despite multiple clinical trials initiating. Drug developers and clinical trial sponsors should monitor emerging mechanistic data before committing to broad PSMA-RLT + PARPi programs. The ClinicalTrials.gov registry provides the latest status on these initiated trials.
For a comprehensive view of PSMA-directed IP strategy, explore PatSnap's patent analytics platform and how leading pharma teams use PatSnap to identify white-space opportunities before competitors.
PSMA-Targeted Therapy Beyond Lu-177 — Key Questions Answered
PSMA (prostate-specific membrane antigen, also designated folate hydrolase 1 / glutamate carboxypeptidase II) is a type II integral transmembrane glycoprotein overexpressed on prostate cancer epithelial cells at levels up to 1,000-fold above normal tissue, with expression increasing proportionally with tumor grade, androgen independence, and metastatic stage. Its folate hydrolase, carboxypeptidase, and internalization activities make it critical for intracellular delivery of cytotoxic payloads including radioligands, ADC warheads, and aptamers.
Three principal alpha-emitting isotopes are under active investigation for PSMA-targeted therapy: Actinium-225 (²²⁵Ac), the most clinically advanced, with documented complete response cases and cohort studies; Lead-212 (²¹²Pb), an in vivo alpha generator decaying through Bismuth-212, evaluated in multicellular tumor spheroid and murine xenograft models; and Thorium-227 (²²⁷Th), listed as under clinical trial investigation. Alpha emitters deliver high linear energy transfer (LET) radiation, inducing complex DNA double-strand breaks that are less amenable to cellular repair than beta radiation.
Androgen receptor blockade with enzalutamide upregulates PSMA expression 2.2–2.6-fold in PSMA-low prostate cancer cell lines (22Rv1, C4-2, LNCaP), as demonstrated by the University of Duisburg-Essen. This cross-target relationship has direct implications for combining AR pathway inhibitors with PSMA-directed therapies to expand the treatable patient population, particularly for PSMA-low or PSMA-negative disease.
PSA decline ≥50% is reported in 34.5–51% of mCRPC patients across systematic reviews of [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto™), with hematological toxicity generally CTCAE grade 1–2. The agent received FDA approval following the Phase III VISION trial and is the established benchmark against which all next-generation PSMA-targeted approaches are measured.
Ambrx, Inc. holds the most concentrated commercial IP signal in the next-generation PSMA space, with three active patent families covering humanized anti-PSMA antibody drug conjugates across EP and IL jurisdictions, all deriving from a 2018 US provisional filing. Novartis AG holds one pending patent (BR) directed at extending the ¹⁷⁷Lu-PSMA-617 label to taxane-naïve mCRPC patients post-ARPI. Alpha therapy IP is currently under-patented relative to scientific activity, representing a potential freedom-to-operate window.
RNA sequencing of 126 primary and 17 metastatic prostate cancer patient samples from Aarhus University Hospital identified a high-risk, immunogenic subset with high CD8⁺ T-cell infiltration and high PSMA expression as candidate responders. This suggests that only a subset of prostate cancer patients are likely candidates for PSMA × CD3 bispecific therapies, making companion diagnostic development essential before clinical translation of PSMA × CD3 bispecifics.
Still have questions about the PSMA-targeted therapy pipeline? Let PatSnap Eureka answer them with live patent and literature data.
Ask PatSnap Eureka About PSMA TherapyAccelerate Your PSMA Pipeline Research with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from alpha-emitter IP gaps to ADC scaffold analysis and bispecific patient stratification signals.
References
- Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts — Tulane University School of Medicine, 2022
- New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen — S. Orsola-Malpighi Hospital, Bologna, 2018
- Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer — University of Duisburg-Essen / DKTK, 2021
- Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with mCRPC — Peter MacCallum Cancer Centre, 2023
- Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer — Erasmus MC, 2022
- Lutetium-177-PSMA therapy for prostate cancer patients — a brief overview of the literature — University Medical Center Utrecht, 2020
- Uses of PSMA-binding radioligand therapeutic agent (RLT) for the treatment of prostate cancer — Novartis AG, 2025, BR [Patent]
- Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer — Technical University of Munich, 2022
- 225Actinium-labeled PSMA targeting peptide induces complete response in a metastatic prostate cancer patient — Istanbul University-Cerrahpasa, 2021
- Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis — Saarland University, 2021
- [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617 — Paul Scherrer Institute / ETH-PSI, 2022
- Humanized Anti-prostate-specific membrane antigen (PSMA) antibody drug conjugates — Ambrx, Inc., 2024, EP [Patent]
- A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile — Johns Hopkins University, 2021
- An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer — Eberhard Karls University Tübingen, 2020
- Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy — Aarhus University Hospital, 2022
- NIH PubMed Central — PSMA expression heterogeneity in prostate cancer research
- European Patent Office — PSMA-targeted therapy patent landscape
- ClinicalTrials.gov — PSMA-targeted therapy and PSMA + PARPi combination trials registry
- American Society of Clinical Oncology — PSMA-targeted therapy in genitourinary oncology
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals only — not a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.